Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial

被引:4
|
作者
Quintana-Hernandez, Domingo J. [1 ]
Rojas-Hernandez, Jaime [2 ]
Santana-Del Pino, Angelo [3 ]
Cespedes Suarez, Carmen [1 ]
Pellejero Silva, Monica [4 ]
Teresa Miro-Barrachina, Maria [5 ]
Ibanez Fernandez, Ignacio [5 ]
Estupinan Lopez, Jose Antonio [2 ]
Borkel, Lucas F. [6 ]
机构
[1] Atlantico Medio Univ, Dept Psychol, Tafira Baja, Spain
[2] Assoc Canaria Desarrollo Salud Traves Atenc, Las Palmas Gran Canaria, Spain
[3] Las Palmas de Gran Canaria Univ, Dept Math, Las Palmas Gran Canaria, Spain
[4] Atlantico Medio Univ, Dept Commun, Tafira Baja, Spain
[5] La Laguna Univ, Dept Clin Psychol Psychobiol & Methodol, San Cristobal la Laguna, Spain
[6] Assoc Cient Psicodel, Las Palmas Gran Canaria, Spain
关键词
Alzheimer's disease; cognitive stimulation; mindfulness; randomized clinical trial; relaxation; EPIDEMIOLOGY; DEMENTIA;
D O I
10.3233/JAD-220889
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: This longitudinal study addressed whether mindfulness practice prevents psychological and behavioral symptoms, especially mood disorders, in Alzheimer's disease (AD). Objective: To assess the incidence of depression in the course of AD and to determine which non-pharmacological treatment (NPT) is most effective in preventing psychopathological symptoms. Methods: We conducted a longitudinal, non-inferiority and equivalence randomized clinical trial, repeated-measures design, with a control group and three experimental treatments: mindfulness, cognitive stimulation, and relaxation. Each experimental group performed three weekly sessions for two years. The pharmacological treatment of all participants was donepezil (10 mg). Participants were patients with probable AD without diagnosed depression from the public neurology services of the Canary Health Service, Spain. Psychological evaluation was performed using the Geriatric Depression Scale (GDS), Hamilton Depression Rating Scale (HDRS), and Neuropsychiatric Inventory (NPI-Q). The statistical analysis included only patients who attended at least 75% of the sessions. A nonparametric, repeated-measures analysis was performed with Kruskal-Wallis H test and between-group differences with Mann-Whitney U test with Bonferroni correction (p < 0.008). Effect size was calculated with partial eta-squared. Results: The results showed significant differences with large effect sizes (eta(2)(p)>0.14) between mindfulness and the rest of the experimental groups as well as the control in the GDS, HDRS, and NPI-Q scales. Conclusion: Compared to the other experimental groups, only mindfulness prevented the onset of depression and other psychopathologies in early-stage AD. Based on its effectiveness in maintaining cognitive functions and preventing psychopathology, we recommend mindfulness as the first-choice NPT for mild to moderate AD.
引用
收藏
页码:471 / 481
页数:11
相关论文
共 50 条
  • [21] Memantine, monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial
    Pomara, N
    Peskind, ER
    Potkin, SG
    McDonald, S
    Xie, Y
    Gergel, I
    NEUROBIOLOGY OF AGING, 2004, 25 : S19 - S19
  • [22] Verbal Repetition in People With Mild-to-Moderate Alzheimer Disease A Descriptive Analysis From the VISTA Clinical Trial
    Cook, Cheryl
    Fay, Sherri
    Rockwood, Kenneth
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2009, 23 (02): : 146 - 151
  • [23] Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease A Phase 2 Randomized Clinical Trial
    Schneider, Lon S.
    Thomas, Ronald G.
    Hendrix, Suzanne
    Rissman, Robert A.
    Brewer, James B.
    Salmon, David P.
    Oltersdorf, Tilman
    Okuda, Tomohiro
    Feldman, Howard H.
    Schneider, Lon S.
    Farlow, Martin
    Ferris, Steven
    Galvin, James
    Porsteinsson, Anton
    Sabbagh, Marwan
    Sano, Mary
    Tariot, Pierre N.
    Ala, Thomas
    Yuan, Shauna
    Heidebrink, Judith
    Bell, Karen
    Aloysi, Amy
    Aggarwal, Neelum
    Duara, Ranjan
    Arnold, Steven
    Karlawish, Jason
    Murphy, Richard Ronan
    Lopez, Oscar
    Porsteinsson, Anton
    Burns, Jeffrey
    Jefferson, Angela
    Farlow, Martin
    van Dyck, Christopher
    Hishaw, G. Alexander
    Pomara, Nunzio
    Turner, Raymond Scott
    Siegal, Alan
    Sabbagh, Marwan
    Zamrini, Edward
    Stern, Robert
    Lerner, Alan
    Capote, Horacio
    Asthana, Sanjay
    Potkin, Steven
    Burke, William
    Schultz, Susan
    Miller, Delwyn
    Sink, Kaycee
    Bernick, Charles
    Murman, Daniel
    JAMA NEUROLOGY, 2019, 76 (11) : 1330 - 1339
  • [24] Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial
    Cook, Cheryl
    Fay, Sherri
    Rockwood, Kenneth
    INTERNATIONAL PSYCHOGERIATRICS, 2008, 20 (05) : 952 - 963
  • [25] Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial
    Dubois, Bruno
    Lopez-Arrieta, Jesus
    Lipschitz, Stanley
    Triantafyllos, Doskas
    Spiru, Luiza
    Moroz, Svitlana
    Venger, Olena
    Vermersch, Patrick
    Moussy, Alain
    Mansfield, Colin D. D.
    Hermine, Olivier
    Tsolaki, Magda
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [26] Virtual Reality-Based Cognitive Stimulation on People with Mild to Moderate Dementia due to Alzheimer's Disease: A Pilot Randomized Controlled Trial
    Oliveira, Jorge
    Gamito, Pedro
    Souto, Teresa
    Conde, Rita
    Ferreira, Maria
    Corotnean, Tatiana
    Fernandes, Adriano
    Silva, Henrique
    Neto, Teresa
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (10)
  • [27] Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
    Bruno Dubois
    Jesús López-Arrieta
    Stanley Lipschitz
    Triantafyllos Doskas
    Luiza Spiru
    Svitlana Moroz
    Olena Venger
    Patrick Vermersch
    Alain Moussy
    Colin D. Mansfield
    Olivier Hermine
    Magda Tsolaki
    Alzheimer's Research & Therapy, 15
  • [28] Misplacing objects in mild to moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial
    Hamilton, L.
    Fay, S.
    Rockwood, K.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (09): : 960 - 965
  • [29] Effectiveness of balance training exercise in people with mild to moderate severity Alzheimer's disease: Protocol for a randomised trial
    Hill K.D.
    LoGiudice D.
    Lautenschlager N.T.
    Said C.M.
    Dodd K.J.
    Suttanon P.
    BMC Geriatrics, 9 (1)
  • [30] Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease - A randomized controlled trial
    Mulnard, RI
    Cotman, CW
    Kawas, C
    van Dyck, CH
    Sano, H
    Doody, R
    Koss, E
    Pfeiffer, E
    Jin, S
    Gamst, A
    Grundman, M
    Thomas, R
    Thal, LJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (08): : 1007 - 1015